Balyasny Asset Management L.P. Increases Stock Position in Xilio Therapeutics, Inc. (NASDAQ:XLO)

Balyasny Asset Management L.P. lifted its holdings in Xilio Therapeutics, Inc. (NASDAQ:XLO) by 26.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 343,230 shares of the company’s stock after acquiring an additional 70,744 shares during the quarter. Balyasny Asset Management L.P.’s holdings in Xilio Therapeutics were worth $328,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Aptus Capital Advisors LLC purchased a new stake in shares of Xilio Therapeutics in the 4th quarter worth approximately $39,000. Gilead Sciences Inc. purchased a new stake in shares of Xilio Therapeutics in the 4th quarter worth approximately $8,696,000. Raymond James Financial Inc. purchased a new stake in Xilio Therapeutics during the fourth quarter valued at approximately $48,000. Renaissance Technologies LLC lifted its position in Xilio Therapeutics by 11.4% during the fourth quarter. Renaissance Technologies LLC now owns 296,617 shares of the company’s stock valued at $283,000 after acquiring an additional 30,317 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Xilio Therapeutics by 6.0% during the fourth quarter. Geode Capital Management LLC now owns 358,422 shares of the company’s stock valued at $342,000 after acquiring an additional 20,230 shares during the last quarter. Hedge funds and other institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Stock Up 7.4%

NASDAQ:XLO opened at $0.86 on Friday. Xilio Therapeutics, Inc. has a 52 week low of $0.62 and a 52 week high of $1.70. The firm has a 50 day moving average of $0.76 and a 200 day moving average of $0.92. The stock has a market capitalization of $44.50 million, a price-to-earnings ratio of -0.50 and a beta of -0.27.

Xilio Therapeutics (NASDAQ:XLO) last posted its earnings results on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.28). The company had revenue of $2.93 million for the quarter, compared to the consensus estimate of $42.00 million. As a group, analysts expect that Xilio Therapeutics, Inc. will post -1.14 EPS for the current year.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.